FrancophonIA/ELRC3.0 huggingface dataset:
English: This means that Clopidogrel Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Maltese: Clopidogrel Teva huwa ‘mediċina ġenerika' li jfisser li Clopidogrel Teva huwa simili għall-‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem Plavix.
English: What are the benefit and risk of Clopidogrel Teva?
Maltese: X'inhu l-benefiċċju u r-riskju ta' Clopidogrel Teva?
English: Because Clopidogrel Teva is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Maltese: Billi Clopidogrel Teva huwa mediċina ġenerika, l-istudji ġew limitati għal testitjiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċina ta' referenza, Plavix.
English: What is Clopidogrel Teva?
Maltese: Kif jintuża Clopidogrel Teva?
English: It can also be used in patients who do not have this abnormal reading on the ECG, if they have unstable angina (a severe type of chest pain) or ‘non-Q-wave' myocardial infarction.
Maltese: Jista' jintuża wkoll f'pazjenti li ma jkollhomx din l-anomalija fl-ECG, jekk ikollhom anġina instabbli (uġigħ gravi fis-sider) jew li jkollhom infart mijokardiku ‘mhux talmewġa Q' (‘non-Q-wave').
English: Because Clopidogrel Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Maltese: Billi Clopidogrel Teva huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, ilbenefiċċju u r-riskju tiegħu huma meqjusa l-istess bħal dawk tal-mediċina ta' referenza.
English: Why has Clopidogrel Teva been approved?
Maltese: Għaliex ġie approvat Clopidogrel Teva?
English: Clopidogrel Teva is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Maltese: Għal xiex jintuża Clopidogrel Teva? Clopidogrel Teva jintuża f'adulti biex jipprevjeni każijiet aterotrombotiċi (problemi li jirriżultaw minn demm magħqud u t-twebbis tal-arterji).
English: Other information about Clopidogrel Teva:
Maltese: Aktar tagħrif ieħor dwar Clopidogrel Teva:
English: Clopidogrel Teva can be started between a few days and 35 days after the attack;
Maltese: Clopidogrel Teva jista' jinbeda fl-ewwel ftit jiem wara l-attakk u sa 35 ġurnata wara;
English: How has Clopidogrel Teva been studied?
Maltese: Kif ġie studjat Clopidogrel Teva?
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Clopidogrel Teva has been shown to have comparable quality and to be bioequivalent to Plavix.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, Clopidogrel Teva wera li għandu kwalità komparabbli ma' u huwa bijoekwivalenti għal Plavix.
English: Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Maltese: Clopidogrel iwaqqaf ilplatelets milli jaggregaw billi jimblokka sustanza msejħa ADP milli tingħaqad ma' riċettur speċjali preżenti fuq is-superfiċje tagħhom.
English: Further information on Pelgraz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Pelgraz is a ‘biosimilar medicine'.
Maltese: Pelgraz huwa “mediċina bijosimili”.
English: The active substance in Pelgraz, pegfilgrastim, consists of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).
Maltese: Is-sustanza attiva f'Pelgraz, il-pegfilgrastim, hija magħmula minn filgrastim, li hija simili ħafna għal proteina tal-bniedem imsejħa fattur stimolanti tal-kolonja tal-granuloċiti (G-CSF).
English: The reference medicine for Pelgraz is Neulasta.
Maltese: Il-mediċina ta' referenza għal Pelgraz hija Neulasta.
English: Other information about Pelgraz
Maltese: Informazzjoni oħra dwar Pelgraz
English: In addition, a study involving 589 patients who had chemotherapy after surgery for breast cancer showed that Pelgraz was as effective as Neulasta in reducing the duration of neutropenia.
Maltese: Barra minn hekk, studju li involva 589 pazjent li ħadu l-kimoterapija wara kirurġija għall-kanċer tassider wera li Pelgraz kien effettiv daqs Neulasta fit-tnaqqis tat-tul ta' newtropenija.
English: Laboratory studies comparing Pelgraz with Neulasta have shown that the active substance in Pelgraz is highly similar to that in Neulasta in terms of structure, purity and biological activity.
Maltese: Studji fil-laboratorji li jqabblu Pelgraz ma' Neulasta wrew li s-sustanza attiva f'Pelgraz hija simili ħafna għal dik f'Neulasta f'termini ta' struttura, purità u attività bijoloġika.
English: Neutropenia lasted on average 1.6 days with both medicines.
Maltese: Bħala medja, innewtropenija damet 1.6 jiem biż-żewġ mediċini.
English: In Pelgraz, filgrastim has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Maltese: F'Pelgraz, filgrastim ġie “pegilat” (twaħħal ma' kimika msejħa polietilenglikol).
English: Pelgraz is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Maltese: Pelgraz jingħata bħala doża waħda ta' 6 mg li tiġi injettata taħt il-ġilda mill-inqas 24 siegħa wara t-tmiem ta' kull ċiklu ta' kimoterapija (kura b'mediċini tal-kanċer).
English: What are the risks associated with Pelgraz?
Maltese: X'inhuma r-riskji assoċjati ma' Pelgraz?
English: Pelgraz is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, , which can develop into leukaemia).
Maltese: Pelgraz mhuwiex maħsub biex jintuża f'pazjenti bil-lewkimja majelojde kronika tal-kanċer tad-demm jew b'sindromi majelodisplastiċi (kundizzjonijiet li fihom jiġu prodotti għadd kbir ta' ċelloli tad-demm anormali, li jistgħu jiżviluppaw f'lewkimja).
English: As for all medicines, data on the use of Pelgraz are continuously monitored.
Maltese: Bħal għall-mediċini kollha, id-data dwar l-użu ta' Pelgraz hija ssorveljata kontinwament.
English: All these data were considered sufficient to conclude that Pelgraz will behave in the same way as Neulasta in terms of effectiveness and safety in its approved uses.
Maltese: Din id-data kollha ġiet meqjusa biżżejjed sabiex jiġi konkluż li Pelgraz ser jaġixxi bl-istess mod bħal Neulasta f'termini ta' effettività u sigurtà fl-użu approvat tiegħu.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Pelgraz has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.
Maltese: L-Aġenzija Ewropea għall-Mediċini ddeċidiet li, b'mod konformi mar-rekwiżiti tal-UE għal mediċini bijosimili, Pelgraz għandu struttura, purità u attività bijoloġika simili ħafna għal Neulasta u jiġi distribwit bl-istess mod fil-ġisem.
English: This means that Pelgraz is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Maltese: Dan ifisser li Pelgraz huwa simili ħafna għal mediċina bijoloġika oħra (il-“mediċina ta' referenza”) li diġà hija awtorizzata fl-UE.
English: It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).
Maltese: Dan jingħata speċifikament biex jitnaqqas it-tul tan-newtropenija u biex tiġi evitata n-newtropenija bid-deni (meta n-newtropenija tkun akkumpanjata minn deni).
English: Pelgraz received a marketing authorisation valid throughout the EU on 21 September 2018.
Maltese: Pelgraz (pegfilgrastim) EMA/518618/2018
English: Pelgraz is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.
Maltese: Pelgraz huwa mediċina li tintuża f'pazjenti bil-kanċer biex tgħin fin-newtropenija (livelli baxxi ta' newtrofili, tip ta' ċellola bajda tad-demm), li hija effett sekondarju komuni tal-kura tal-kanċer u tista' twassal biex il-pazjenti jsiru vulnerabbli għall-infezzjonijiet.
English: What measures are being taken to ensure the safe and effective use of Pelgraz?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Pelgraz?
English: For the full list of side effects and restrictions with Pelgraz, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u rrestrizzjonijiet b'Pelgraz, ara l-fuljett ta' tagħrif.
English: Side effects reported with Pelgraz are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Pelgraz huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: Page 2/2©EMEA 2006
Maltese: Paġna 2/2©EMEA 2006
English: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Maltese: (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: Other information about Ypozane:
Maltese: Informazzjoni oħra dwar Ypozane:
English: The medicine is available as 1.875 mg, 3.75 mg, 7.5 mg or 15 mg tablets, which can be used for dogs of different weights (small, medium sized, large or very large dogs).
Maltese: Il-mediċina tiġi bħala pilloli tal-1.875 mg, 3.75 mg, 7.5 mg jew 15 mg, li tista' tintuża għal klieb ta' piż differenti (klieb żgħar, ta' daqs medju, kbar jew kbar ħafna).
English: Why has Ypozane been approved?
Maltese: Għaliex ġie approvat Ypozane?
English: The prostate is a gland that produces a fluid that is part of the semen.
Maltese: Il-prostata hija glondola li tipproduċi fluwidu li huwa parti mill-fluwidu seminali.
English: The dogs received once a day for 7 days, one Ypozane tablet appropriate for their size to correspond to a daily dose of 0.250.5 mg osaterone acetate per kilogram bodyweight.
Maltese: Il-klieb ingħataw pillola ta' Ypozane darba kuljum għal sebat ijiem adattata għad-daqs tagħhom biex jieħdu doża ta' 0.25 - 0.5 mg osaterone aċetat għal kull kilogramma li jiżnu, kuljum.
English: Ypozane are round, white tablets that contain osaterone acetate as the active substance.
Maltese: Ypozane huma pilloli tondi, bojod li fihom osaterone aċetat bħala sustanza attiva.
English: In female laboratory animals, osaterone acetate caused serious adverse effects on reproductive functions.
Maltese: Fl-annimali tal-laboratorju nisa, osaterone aċetat ikkawża effetti sekondarji serji fuq ilfunzjonijiet riproduttivi.
English: In male dogs, it blocks the transport of the male hormone testosterone into the prostate.
Maltese: Fil-klieb irġiel jimblokka t-trasport ta' l-ormon maskili testosteron fil-prostata.
English: Osaterone acetate is a hormone that is chemically related to progesterone, and as such it has anti-androgen and progestagen activity.
Maltese: Osaterone aċetat huwa ormon li huwa kimikament relatat mal-proġesteron, u għalhekk għandu attività antiandroġena u prostaġenika.
English: This summary was last updated on 11.01.2007.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fil-11.01.2007.
English: The effectiveness of osaterone acetate was investigated in a large study undertaken in a number of veterinary practices across Europe.
Maltese: L-effettività ta' osaterone aċetat ġiet investigata fi studju kbir li sar f'diversi kliniċi veterinarji madwar l-Ewropa.
English: What is Ypozane?
Maltese: Kif jaħdem Ypozane ?
English: Wash hands after administration.
Maltese: Aħsel idejk wara l-amministrazzjoni.
English: Data were provided on the pharmaceutical quality of the product, the tolerance of Ypozane in dogs and the safety of the tablets when handled by humans.
Maltese: Ġiet ipprovduta dejta dwar il-kwalità farmaċewtika tal-prodott, it-tolleranza ta' Ypozane filklieb u s-sigurtà tal-pilloli meta jiġu mmaniġġjati mill-bniedem.
English: Dogs with enlarged prostates from various breeds, age groups and weights, were either treated with Ypozane or with another product, which is already authorised in the EU for this indication.
Maltese: Klieb bil-prostata kbira minn razez, gruppi ta' età u piż differenti ġew ittrattati b'Ypozane jew bi prodott ieħor, li diġà huwa awtorizzat fl-UE għal din l-indikazzjoni.
English: Ypozane is used in male dogs for the treatment of “benign prostatic hypertrophy”, which means an increase of the size of the prostate gland that is not related to cancer (benign).
Maltese: Ypozane jintuża fil-klieb irġiel għat-trattament ta' l-“ipertrofija prostatika beninja”, li tfisser żieda fid-daqs tal-prostata mhux relatata ma' kanċer (beninja).
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Ypozane exceed its risks for the treatment of benign prostatic hypertrophy (BPH) in male dogs and recommended that Ypozane be given a marketing authorisation.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għal Użu Veterinarju (CVMP) ikkonkluda li l-benefiċċji ta' Ypozane huma ikbar mir-riskji tiegħu għat-trattament ta' l-ipertrofija prostatika beninja (BPH) fil-klieb irġiel u rrakkomanda li Ypozane jingħata l-awtorizzazzjoni għat-tqegħid fissuq.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Ypozane to Virbac S.A. on 11.01.2007.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fuq is-suq madwar l-Unjoni Ewropea, għal Ypozane lil Virbac S.A. fil-11.01.2007.
English: What is the risk associated with Ypozane?
Maltese: X'inhu r-riskju assoċjat ma' Ypozane?
English: Ypozane has no adverse effects on semen quality.
Maltese: Ypozane ma għandux effetti severi fuq il-kwalità tal-fluwidu seminali.
English: The benefitrisk balance may be found in module 6 of this EPAR.
Maltese: Il-bilanċ bejn il-benefiċċju u r-riskju jinsab fil-modulu 6 ta' din l-EPAR.
English: By inhibiting testosterone, Ypozane helps the prostate to shrink back to its normal size.
Maltese: Bl-inibizzjoni tat-testosteron, Ypozane jgħin lill-prostata tinxtorob lura għad-daqs normali tagħha.
English: Treatment with Ypozane was effective in the treatment of benign prostatic hypertrophy.
Maltese: It-trattament b'Ypozane kien effikaċi fit-trattament ta' l-ipertrofija prostatika beninna.
English: After this time, the dog should be re-examined by a veterinarian and treatment might be repeated.
Maltese: Wara dan iż-żmien, il-kelb ikun irid jiġi eżaminat mill-ġdid minn veterinarju u t-trattament jista' jiġi ripetut.
English: Some dogs might also show vomiting, diarrhoea or increased thirst, or might develop a “feminisation syndrome”.
Maltese: Xi klieb jista' jkollhom ukoll remettar, dijarea jew żieda fil-għatx, jew jistgħu jiżviluppaw “sindromu ta' feminizzazzjoni”.
English: PSURs FUM and SO
Maltese: PSURs FUM u SO
English: Status vaccines: Sections 4 and 5
Maltese: Guideline on product information for vaccines: Sections 4 and 5
English: Technical Requirements for Blood and Blood Components (including those used for medicinal products derived from human blood and plasma)
Maltese: Blood Components (including those used for medicinal products derived from human blood and plasma)
English: 2004 final
Maltese: 2004 finali
English: Need for revision of the current SPC guideline to give precise recommendation on prudent use and restrictions based on resistance data evolving from the SPC guideline
Maltese: guideline to give precise recommendation on prudent use and restrictions based on resistance data evolving from the SPC guideline
English: Guideline on similar medicinal products containing biotechnology derived proteins as active substances: Quality issues
Maltese: Guideline on similar medicinal products containing biotechnology derived proteins as active substances:
English: 2003 final
Maltese: 2003 finali
English: CHMP Concept paper and guideline on quality requirements for manufacturing in and distribution from climatic zones 3 and 4
Maltese: CHMP Concept paper and guideline on quality requirements for manufacturing in and distribution from climatic zones
English: ICH E14 the clinical evaluation of QT/QTs interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs
Maltese: ICH E14 the clinical evaluation of QT/QTs interval prolongation and proarrhythmic potential for non antiarrhythmic drugs
English: The total in 2005 is expected to reach € 33,498,000
Maltese: It-total fl-2005 huwa mistenni jilħaq € 33,498,000
English: Category & Grade
Maltese: & Grad
English: The Paediatrics Working Party will be consulted at an early stage of the drafting of guidelines which are relevant to paediatric population developed by any CHMP working parties
Maltese: The Paediatrics Working Party will be consulted at an early stage of the drafting of guidelines, which are relevant to paediatric population,
English: VICH Target animal safetypharmaceuticals
Maltese: VICH Target animal safety pharmaceuticals
English: Concurrent administration of IVMPs in view of determining day X to be 14 days and consequent revision of the SPC guideline for immunologicals
Maltese: Concurrent administration of IVMPs in view of determining day X to be 14
English: 4.4 Certificates
Maltese: 4.4 Ċertifikati
English: Number of financial transactions
Maltese: Numru ta' transazzjonijiet finanzjarji
English: Further guidance on interpretation of the data from guideline CVMP-VICH GL27, guidance on pre-approval information for registration of new veterinary medicinal products for foodproducing animals with respect to antimicrobial resistance (CVMP/VICH/644/01)
Maltese: Further guidance on interpretation of the data from guideline CVMP-VICH GL27, guidance on pre-approval information for registration of new veterinary medicinal products for food producing animals with respect to antimicrobial resistance
English: 4.3 Mutual recognition agreements
Maltese: Mutual Recognition Procedure
English: For more information please refer to section 2.12.
Maltese: Għal iktar informazzjoni jekk jogħġobkom irreferu għat-taqsima 2.12.
English: Guideline on requirements for evaluation of new immunological “adjuvants” in vaccines
Maltese: Consultation evaluation of new immunological “adjuvants” in vaccines
English: By 1987, he had gradually moved from full-time interpreting to full-time software development.
Maltese: Sa l-1987, kien għadda gradwalment minn interpretazzjoni full time għal żvilupp tas-software full time.
English: Note for guidance on the clinical investigation of recombinant Factor VIII and IX products (CPMP/BPWG/1561/99) and the Note for guidance on the clinical investigation of human plasma derived Factor VIII and IX products
Maltese: VIII and IX products (CPMP/BPWG/1561/99) and the Note for guidance on the clinical investigation of human plasma derived Factor VIII and IX products
English: Discussion papers on other important organs to be considered when developing medicinal products in neonates complementary to the paper already published on renal maturation (e.g. hepatic, central nervous system)
Maltese: Discussion papers on other important organs to be considered when developing a medicinal products in neonates complementary to the paper already published on renal maturation
English: 22 - 23 November
Maltese: 22 - 23 ta' Novembru
English: Standard Operating Procedure on Urgent Safety Restrictions for Medicinal Products Authorised through Mutual Recognition Procedure
Maltese: Standard Operating Procedure on Urgent Safety Restrictions for Medicinal Products Authorised through
English: Concept paper on impact of analytical methods on Commission Decision 2002/657/EC compared with current analytical requirements for the establishment of MRLs
Maltese: (2002/657/EC) compared with current analytical requirements for the establishment of MRLs
English: ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals
Maltese: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals
English: Number of reimbursed delegates
Maltese: In-Numru ta' delegati rimborzati
English: Guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolism in nonsurgical patients
Maltese: Guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolism in non surgical patients
English: Member of the Pharmaceutical Society of Ireland.
Maltese: Farmaċewtika ta' l-Irlanda.
English: Censor Jurado de Cuentas and Member of the Registro Oficial de Auditores de Cuentas in Spain.
Maltese: Membru ta' l-Istitut ta' Kontabili Elenkati fl-Irlanda. Censor Jurado de Cuentas u Membru tar-Registro Oficial de Auditores de Cuentas fi Spanja.
English: The forecast number of SUSAR reports for 2005 is 8,000
Maltese: In-numru previst ta' rapporti SUSAR għall-2005 huwa ta' 8,000
English: Reimbursed meetings Videoconferences
Maltese: Laqghat rimborzati Vidjokonferenzi
English: 3.7 Regulatory activities
Maltese: 3.7 Attivitajiet regolatorji
English: TEMPORARY POSTS
Maltese: IMPIEGI TEMPORANJI
English: Executive master of business administration from the Centre de Perfectionnement aux Affaires at HEC-CPA, in Jouy-en-Josas, France, in 2000.
Maltese: Master Eżekuttiv fl-Amministrazzjoni Kummerċjali minn Centre de Perfectionnement aux Affaires f'HEC-CPA, f'Jouy-en-Josas, Franza, fl-2000.
English: Note for Guidance on Quality, Preclinical and Clinical Aspects of Gene Transfer Medicines - Lentiviral Vectors
Maltese: Note for Guidance on Quality, Pre clinical and Clinical Aspects of Gene Transfer Medicines - Lentiviral
English: Guideline on the clinical requirements for locally applied, locally acting products containing known constituents
Maltese: Guideline on the clinical requirements for locally applied, locally acting
English: He was also responsible for a laboratory unit.
Maltese: Kien ukoll responsabbli minn laboratorju.
English: (draft budget)
Maltese: (abbozz tal-budget)
English: Biostatistical/methodological issues arising from CHMP discussion on marketing authorisation applications: Choice of non-inferiority margin
Maltese: Biostatistical/methodological issues arising from CHMP discussion on marketing authorisation applications:
English: Revised guideline on specifications: test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products
Maltese: test procedures and acceptance criteria for herbal drugs, herbal drug preparations and herbal medicinal products
English: Policy for the transmission of PhVWP Recommendations and Assessment Reports for mutually recognised and purely nationally authorised products to marketing authorisation holders
Maltese: Reports for mutually recognised and purely nationally authorised products to marketing authorisation holders
English: Career to date: Tim Buxton completed articles with Touche Ross & Co. in London in 1987.
Maltese: Karriera sal-Preżent: Tim Buxton ħadem ma' Touche Ross & Co f'Londra fl-1987.
English: Marijke KORTEWEG Direct telephone (44-20) 74 18 85 56 E-mail: iqmanagement@emea.eu.int
Maltese: Marijke KORTEWEG Telefon dirett (44-20) 74 18 85 56 E-mail: iqmanagement@emea.eu.int
English: 3.9 Coordination group
Maltese: 3.9 Il-Grupp ta' koordinazzjoni
English: From 1974 to 1985, he was an audit manager in Spain with Ernst and Young and from 1985 to 1995 he was financial controller at Johnson Wax Española.
Maltese: kien kap tal-verifika fi Spanja ma' Ernst and Young u mill-1985 sa l-1995 kien Kontrollur Finanzjarju ma' Johnson Wax Española.